Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin add-on to insulin in adults with type 1 diabetes mellitus
NL-OMON43855Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in diabetes mellitus type 1 (T1D) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in HbA1c. Started Sep 2016; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON43855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43855.